Enlivex Therapeutics Ltd.

ENLV · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$2,205-$1,868-$3,452-$5,176
Dep. & Amort.$81$85$90$36
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$295$293$0
Change in WC-$196$172-$470$664
Other Non-Cash$25$90-$1,085$392
Operating Cash Flow-$2,295-$1,198-$4,624-$4,117
Investing Activities
PP&E Inv.-$24-$7-$32-$35
Net Acquisitions$361$0$0$304
Inv. Purchases-$7,369-$7,337-$9,544-$1,266
Inv. Sales/Matur.$11,193$8,169$12,413$4,377
Other Inv. Act.$0$264$336-$21
Investing Cash Flow$4,162$1,089$3,173$3,358
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$376$1$197$1,280
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$0$0$2
Financing Cash Flow$376$1$197$1,261
Forex Effect-$52-$25$0$0
Net Chg. in Cash$2,191-$161-$1,254$535
Supplemental Information
Beg. Cash$2,005$2,166$3,731$3,196
End Cash$4,196$2,005$2,477$3,731
Free Cash Flow-$2,319-$1,205-$4,656-$4,153
Enlivex Therapeutics Ltd. (ENLV) Financial Statements & Key Stats | AlphaPilot